ArticleDiscover oncology2026
Atypical cortical presentation of anti-Ri paraneoplastic encephalitis mimicking tumor.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis report expands the known clinical phenotype of anti-Ri (ANNA-2)-associated paraneoplastic syndrome to include isolated neocortical involvement. METHODS AND
resultsWe report the case of a 54-year-old woman who presented with transient apraxia, confusion, and headache. Brain MRI revealed a tumor-like lesion in the left frontal cortex. Stereotactic brain biopsy showed inflammatory changes without evidence of malignancy. Serum testing was strongly positive for anti-Ri antibodies, and systemic workup identified breast cancer with axillary lymph node metastasis. The patient received breast cancer surgery and chemotherapy alongside high-dose steroid pulse therapy and four weekly doses of rituximab, resulting in marked resolution of the cortical lesion.
conclusionWhile current PNS-Care diagnostic criteria enabled a definitive diagnosis, further investigation is warranted to elucidate the underlying pathomechanism of cortical involvement in anti-Ri paraneoplastic neurological syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.